glp-1 agonists and sglt2 inhibitors combination Diabetic Agents, From Metformin to GLP1 Receptor Agonists: JACC Focus Seminar Metabolic and cardiovascular benefits with
Description
Lancet Oncol
The following is a brief summary of available data from the PIONEER 1-8 studies
Compounded medications are not FDA-approved and are prepared by licensed compounding pharmacies
In the present review, we describe the cardiovascular effects and underlying molecular mechanisms of action of GLP-1RAs in CVOTs, animal models and cultured cells, and address how these findings have transformed our understanding of the pharmacotherapy of T2DM and the prevention of CVD
doi: 10.1016/S2468-2667(21)00228-0 53 ZhaoYHuaXRenXOuyangMChenCLiYet al
